Profile: Pfizer Inc (PFE)
3 May 2016
Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. The Company's biopharmaceutical products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent and the Premarin family of products. The Company's biotechnology products include BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel. In addition, other business activities within the Company include Pfizer CentreSource, its contract manufacturing and bulk pharmaceutical chemical sales operation.
The Company's commercial operations consist of two businesses: Innovative Products business and Established Products business. The Innovative Products business consists of two segments: the Global Innovative Pharmaceutical segment (GIP) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC). The Established Products business consists of the Global Established Pharmaceutical segment (GEP). Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases. In addition, it focuses on biosimilars. The Company has collaboration and/or co-promotion agreements relating to certain biopharmaceutical products, including Enbrel (in the United States and Canada), Spiriva and Rebif. The Company's subsidiary is Hospira, Inc.
The Company's Consumer Healthcare business products are categorized into Dietary Supplements
Pain Management, Gastrointestinal, and Respiratory and Personal Care. The Company's Dietary Supplements products include Centrum brands, which include Centrum, Centrum Silver, Centrum Men's and Women's, Centrum VitaMints, Centrum Specialist, Centrum Flavor Burst and Centrum Kids; Caltrate and Emergen-C. Its Pain Management products include Advil brands, which include Advil, Advil PM, Advil Liqui-Gels, Advil Film Coated, Children's Advil, Infants' Advil and Advil Migraine, and ThermaCare. Its Gastrointestinal products include Nexium 24HR/Nexium Control and Preparation H. The Company's Respiratory and Personal Care include Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp and ChapStick.
Global Innovative Pharmaceutical segment
The Company's Global Innovative Pharmaceutical segment focuses on developing and commercializing medicines that improve patients' lives. The Company's key therapeutic areas include inflammation/immunology, cardiovascular/metabolic, neuroscience/pain and rare diseases. The Company's products include Lyrica, Enbrel, Viagra, BeneFIX, Chantix/Champix, Refacto AF/Xyntha, Xeljanz and Eliquis.
Global Vaccines, Oncology and Consumer Healthcare segment
The Company's Global Vaccines, Oncology and Consumer Healthcare segment focuses on the developing and commercializing vaccines and products for oncology and consumer healthcare. Consumer Healthcare manufactures and markets various well-known, over-the-counter (OTC) products. The Company's products include Prevnar/Prevenar 13, Sutent, Ibrance, Xalkori and Inlyta.
Global Established Pharmaceutical segment
The Company's Global Established Pharmaceutical segment includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars and infusion systems. The product categories in its Global Established Products segment include Legacy Established Products, Peri-LOE Products, Sterile Injectable Pharmaceuticals, Infusion Systems, Biosimilars and Other Established Products. Its Legacy Established Products include products that have lost patent protection. Its Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include Celebrex, Zyvox and Revatio in most developed markets, Lyrica in the EU, Pristiq in the United States and Inspra in the European Union. The Company's Sterile Injectable Pharmaceuticals include generic injectables and specialty injectables. The Company's Infusion Systems include medication management systems products composed of infusion pumps and related software and services, as well as intravenous therapy (I.V.) infusion products, including large volume I.V. solutions and their associated administration sets. The Company's Biosimilars include Inflectra (biosimilar infliximab) in Canada, Mexico, Australia and certain European markets, Nivestim (biosimilar filgrastim) in Australia and certain European and Asian markets and Retacrit (biosimilar epoetin) in certain European markets. The Company's Other Established Products include Hospira's One-to-One contract manufacturing and bulk pharmaceutical chemical sales organizations.
235 E 42ND ST
NEW YORK NY 10017-5703
Company Web Links
- Biotech stock swoon sparks buyout interest: investor
- M&A slowdown clouds Wall Street view on stocks
- Exclusive: Pfizer approaches Medivation about potential takeover - sources
- Pfizer CEO still interested in deals after losing Allergan
- BRIEF-Pfizer says does not expect to seek tax-inversion deals in near term